Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
BlackRock-Led GCC Infrastructure Partnership Targets $30 Billion Investment 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
- NR and NAD+ gaining more attention as consumers continue to look for ways to rejuvenate their energy
IRVINE, Calif., Sept. 22, 2016 -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced leading supplement retailer, Vitamin Shoppe, featured NIAGEN® nicotinamide riboside (NR) in their Hot Ingredient Spotlight section in the Fall 2016 print edition of their Amazing Wellness magazine.
ChromaDex founder and CEO, Frank Jaksch, Jr. commented, “As the aging population continues to grow, their interest in what can be done to rediscover that sense of vitality or youthful energy grows. The scientific evidence validating NR’s ability to increase cellular NAD+, has people interested and wanting to learn more.” Jaksch continued, “This type of coverage is a perfect complement to the ongoing consumer outreach we are doing to help people understand that the answer lies within their own cells.”
About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 2, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Public Relations Contact: Breah Ostendorf, Director of Marketing 949-537-4103 [email protected] ChromaDex Investor Relations Contact: Andrew Johnson, Director of Investor Relations 949-419-0288 [email protected]
